COL114883-TaqPath RNase P 2.0 Image-1400x400

Prepare for emerging mutations with an advanced COVID-19 test

Thermo Fisher continues to provide the gold standard of testing with our Emergency Use (EU) Authorized PCR-based TaqPath COVID-19 RNase P Combo Kit 2.0, delivering confidence in your results with an advanced COVID-19 assay design that targets 8 sequences across 3 genomic regions (orf1a, orf1b, and N genes) to compensate for emerging SARS-CoV-2 mutations. This increased target redundancy ensures accurate results even for new mutations, with high sensitivity and specificity, providing confidence in results now and into the future.

Fill out the form, and read the technical bulletin to learn more about the science behind the workflow and performance of the Emergency Use Authorized (EUA) Applied Biosystems TaqPath COVID‑19 RNase P Combo Kit 2.0—designed to detect SARS-CoV-2 from symptomatic and asymptomatic patients with an approximate three-hour turnaround time.

TechBulletinEUA
*
*
*
*
*
*
 
 
For Emergency Use Authorization. For in vitro diagnostics. For Prescription use only.